BMC Medicine (Dec 2022)
Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
- Taku Kinoshita,
- Masahiro Shinoda,
- Yasuhiro Nishizaki,
- Katsuya Shiraki,
- Yuji Hirai,
- Yoshiko Kichikawa,
- Kenji Tsushima,
- Masaharu Shinkai,
- Naoyuki Komura,
- Kazuo Yoshida,
- Yasutoshi Kido,
- Hiroshi Kakeya,
- Naoto Uemura,
- Junichi Kadota
Affiliations
- Taku Kinoshita
- Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital
- Masahiro Shinoda
- Department of Respiratory Medicine, Tokyo Shinagawa Hospital
- Yasuhiro Nishizaki
- Tokai University Tokyo Hospital
- Katsuya Shiraki
- Department of General and Laboratory Medicine, Mie Prefectural General Medical Center
- Yuji Hirai
- Department of Infectious Diseases, Tokyo Medical University Hachioji Medical Center
- Yoshiko Kichikawa
- Department of Respiratory Medicine, Mishuku Hospital
- Kenji Tsushima
- Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital
- Masaharu Shinkai
- Department of Respiratory Medicine, Tokyo Shinagawa Hospital
- Naoyuki Komura
- Clinical Development Planning, Ono Pharmaceutical Co., Ltd.
- Kazuo Yoshida
- Department of Statistical Analysis, Ono Pharmaceutical Co., Ltd.
- Yasutoshi Kido
- Department of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University
- Hiroshi Kakeya
- Department of Infection Control Science, Graduate School of Medicine, Osaka City University
- Naoto Uemura
- Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University
- Junichi Kadota
- Department of Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University
- DOI
- https://doi.org/10.1186/s12916-022-02695-5
- Journal volume & issue
-
Vol. 20,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
